These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 22951782

  • 1. [A combined preparation stalevo in Parkinson's disease: a 5-year experience of continuous dopaminergic stimulation].
    Fedotova EIu, Karabanov AV, Poleshchuk VV, Polevaia EV, Mirkasimov AF, Zagorovskaia TB, Ivanova-Smolenskaia IA, Illarioshkin SN.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5):50-5. PubMed ID: 22951782
    [Abstract] [Full Text] [Related]

  • 2. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
    Silver DE.
    Expert Rev Neurother; 2004 Jul; 4(4):589-99. PubMed ID: 15853578
    [Abstract] [Full Text] [Related]

  • 3. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
    Koller W, Guarnieri M, Hubble J, Rabinowicz AL, Silver D.
    J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197
    [Abstract] [Full Text] [Related]

  • 4. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV, Odinak MM, Mogil'naia VI, Sologub OS, Sakharovskaia AA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009 Feb; 109(1):51-4. PubMed ID: 19156087
    [Abstract] [Full Text] [Related]

  • 5. [The study on the assessment of the new levodopa drug--stalevo (levodopa/carbidopa/entacapone), in treatment of Parkinson's disease in out-patient clinical practice (the results of the open START-M)].
    Boĭko AN, Batysheva TT, Minaeva NG, Babina LA, Vdovichenko TV, Zhuravleva EIu, Shikhkerimov RK, Malykhina EA, Khozova AA, Zaĭtsev KA, Kostenko EV.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007 Feb; 107(12):21-4. PubMed ID: 18427455
    [Abstract] [Full Text] [Related]

  • 6. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [Abstract] [Full Text] [Related]

  • 7. Levodopa/carbidopa/entacapone (Stalevo).
    Hauser RA.
    Neurology; 2004 Jan 13; 62(1 Suppl 1):S64-71. PubMed ID: 14718682
    [Abstract] [Full Text] [Related]

  • 8. Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study).
    Myllylä V, Haapaniemi T, Kaakkola S, Kinnunen E, Hartikainen P, Nuutinen J, Rissanen A, Kuopio AM, Jolma T, Satomaa O, Heikkinen H.
    Acta Neurol Scand; 2006 Sep 13; 114(3):181-6. PubMed ID: 16911346
    [Abstract] [Full Text] [Related]

  • 9. [The use of stalevo in the treatment of patients with Parkinson's disease].
    Kretova AS, Lyubimov AV.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014 Sep 13; 114(10):35-8. PubMed ID: 25591514
    [Abstract] [Full Text] [Related]

  • 10. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
    Castro A, Valldeoriola F, Linazasoro G, Rodriguez-Oroz MC, Stochi F, Marin C, Rodriguez M, Vaamonde J, Jenner P, Alvarez L, Pavon N, Macias R, Luquin MR, Hernandez B, Grandas F, Gimenez-Roldan S, Tolosa E, Obeso JA.
    Neurologia; 2005 May 13; 20(4):180-8. PubMed ID: 15891947
    [Abstract] [Full Text] [Related]

  • 11. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
    Brooks DJ, Agid Y, Eggert K, Widner H, Ostergaard K, Holopainen A, TC-INIT Study Group.
    Eur Neurol; 2005 May 13; 53(4):197-202. PubMed ID: 15970632
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial).
    Boiko AN, Batysheva TT, Minaeva NG, Babina LA, Vdovichenko TV, Zhuravleva EY, Shikhkerimov RK, Malykhina EA, Khozova AA, Zaitsev KA, Kostenko EV.
    Neurosci Behav Physiol; 2008 Nov 13; 38(9):933-6. PubMed ID: 18975095
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Nocturnal motor symptoms of Parkinson's disease and their treatment with the three-component drug levodopa/carbidopa/entacapone].
    Kulua TK, Fedorova NV, Popovkina OA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011 Nov 13; 111(9 Pt 2):45-50. PubMed ID: 22027607
    [Abstract] [Full Text] [Related]

  • 19. Levodopa/carbidopa/entacapone in Parkinson's disease.
    Seeberger LC, Hauser RA.
    Expert Rev Neurother; 2009 Jul 13; 9(7):929-40. PubMed ID: 19589043
    [Abstract] [Full Text] [Related]

  • 20. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
    Reichmann H, Emre M.
    Expert Rev Neurother; 2012 Feb 13; 12(2):119-31. PubMed ID: 22288667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.